Genomics Promised Tailored Medicine. Aging Research Is Repeating the Mistake.

Biochemists now map the precise ways individual aging trajectories diverge at the cellular level. Different people accumulating different types of damage in different tissues at different rates.

This confidence is new, though molecular heterogeneity is not. The finding is real, yet the problem lies in what happens next, where a historical pattern begins to repeat itself.

Twenty years ago, the Human Genome Project declared victory and pivoted to variation. Personalized medicine was imminent, with Francis Collins, then director of the National Institutes of Health, calling it the future of healthcare because individual genetic variation promised individual risk prediction and intervention.

By 2015, almost none of it had materialized. Variation exceeded our ability to predict or act on it. Genetic variants that increased risk in one population conferred none in another, while environmental and behavioral factors scrambled every neat correlation. Treatments still targeted population categories because that was all that actually worked. The gap between discovery and application became permanent. Aging research is following the identical path, just with molecular signatures instead of SNPs. The rhetoric has already shifted toward tailored interventions as if the questions were already answered.

The difference that matters is whether anyone in the longevity field remembers the genomics cycle. If they do, they build humility into funding and timelines. If they don't, they recruit investors and journalists who repeat the same predictions, watch five years pass, then act surprised when interventions remain population-wide. The real question is not whether people age differently. It's whether we learned that seeing variation and being able to use it are not the same discovery.